Akari Therapeutics Presents Positive Preclinical Data for AKTX-101
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Akari Therapeutics announced the presentation of positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, at the American Association for Cancer Research, AACR, Annual Meeting 2026. Unlike current TROP2-targeting ADCs that use Topoisomerase I Inhibitor payloads, AKTX-101 has the potential to address resistance to Topoisomerase I Inh. ADCs and contribute to durable anti-tumor efficacy due to the payload's unique cytotoxic and immune-activating mechanisms of action. The preclinical data compares the performance of AKTX-101 versus TROP2 ADCs with Topoisomerase I Inh. payloads in the killing of different cancer types driven by different cancer genes. AKTX-101's ability to kill cancer cells at lower concentrations vs. TROP2 ADCs using Topoisomerase I Inh. payloads suggests that AKTX-101 is a more potent drug.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AKTX
Wall Street analysts forecast AKTX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.140
Low
1.00
Averages
3.33
High
7.00
Current: 5.140
Low
1.00
Averages
3.33
High
7.00
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Sector Attracts Investor Attention Amid Innovation
- Investor Enthusiasm: The biotech sector is attracting significant speculative capital due to innovations in next-generation oncology, metabolic diseases, and CNS therapy platforms, indicating strong market interest that could drive stock prices of related companies higher.
- Akari Therapeutics New Data: Akari Therapeutics' ADC candidate AKTX-101 demonstrated synergistic activity in KRAS-mutated pancreatic cancer models, further expanding the potential of its RNA spliceosome-modulating payload platform, which may open new market opportunities for the company.
- NeOnc Technologies Analyst Focus: NeOnc Technologies is gaining attention for its neuro-oncology platform targeting the blood-brain barrier, with multiple analysts issuing “Buy” ratings, which is expected to enhance the company's visibility ahead of anticipated clinical updates.
- MetaVia Research Findings: MetaVia's GPR119 agonist vanoglipel has shown anti-fibrotic potential in new research, indicating its promise in treating metabolic dysfunction-associated steatohepatitis, which may attract further investor interest as clinical data develops.
See More
Akari Therapeutics Shares Surge Over 100% on Breakthrough Data
- Breakthrough Clinical Data: Akari Therapeutics reported that its antibody-drug conjugate AKTX-101 demonstrated synergistic anti-cancer activity when combined with KRAS inhibitor Adagrasib in KRAS-mutated pancreatic cancer models, indicating a potentially powerful combination therapy.
- Efficacy Validation: AKTX-101 achieved Bliss synergy scores exceeding 10 in KRAS-mutant pancreatic cancer cell lines, while traditional TROP2 ADC combinations showed antagonistic effects, underscoring the unique biological mechanism of Akari's PH1 payload.
- Clinical Trial Plans: Akari has initiated IND-enabling studies for AKTX-101 and aims to start its first-in-human clinical trial by mid-2027, showcasing the company's forward-looking strategy in cancer treatment.
- Strong Market Reaction: In pre-market trading, AKTX shares surged from $5.14 to $10.57, reflecting an over 100% increase, indicating high investor confidence and recognition of the new data.
See More
Akari's Cancer Therapy Data Sparks 120% Stock Surge
- Preclinical Data Breakthrough: Akari Therapeutics announced that its lead cancer therapy, AKTX-101, demonstrates strong tumor-killing activity when combined with KRAS inhibitors, particularly in pancreatic cancer models, leading to a 120% surge in shares during after-hours trading, reflecting high market recognition of the therapy's potential.
- Expanded Treatment Opportunities: This data not only supports further development of AKTX-101 but also indicates the broader applicability of RNA splicing-targeted therapies in treating difficult KRAS-driven cancers, potentially transforming current treatment strategies and improving patient survival rates.
- Combination Therapy Advantage: In studies combining AKTX-101 with adagrasib (a KRAS inhibitor), synergistic cell killing was observed in KRAS G12D and G12C mutant cell lines, while other TROP2 ADCs exhibited antagonism, highlighting the unique biological mechanism of AKTX-101.
- Clinical Trial Plans: Akari has initiated IND-enabling studies for AKTX-101, targeting the start of its first-in-human clinical trial by mid-2027, and despite a 55% year-to-date decline in share price, this data release may provide momentum for future clinical advancements.
See More
Multiple Companies Experience Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
- AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
- P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
- Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
See More
Akari Therapeutics Begins Human Trials for AKTX-101
- Preclinical Data Breakthrough: Akari Therapeutics' AKTX-101 demonstrated significantly enhanced efficacy against pancreatic cancer cells with KRAS mutations in lab tests when combined with an approved cancer drug, indicating its potential in treating difficult cancers.
- Funding for Development: The company raised approximately $5.5 million through a private placement, which will be utilized to advance AKTX-101 towards human testing and cover general corporate needs, reflecting strong confidence from strategic investors in the company's future.
- Stock Price Surge: Following the announcement of breakthrough preclinical data, Akari's shares skyrocketed over 133% in after-hours trading, showcasing a strong bullish sentiment in the market, particularly among retail investors whose sentiment shifted from neutral to extremely bullish.
- Optimistic Analyst Ratings: Among the two analysts covering AKTX, one rates it a 'Buy' while the other maintains a 'Hold', with a 12-month average price target of $26.78, suggesting a potential upside of over 420%, despite the stock having fallen 90% over the past year.
See More
Akari Therapeutics' Novel ADC Shows Promise Against KRAS-Driven Cancers
- Novel Drug Combination: Akari Therapeutics' AKTX-101, when combined with the KRAS inhibitor adagrasib, demonstrates synergistic cytotoxic activity in KRAS G12D and G12C mutated pancreatic cancer models, indicating its potential application in difficult-to-treat KRAS-driven cancers.
- Preclinical Data Support: The online abstract presented at the 2026 ASCO Annual Meeting highlights the significant differences of AKTX-101's unique RNA splicing modulator payload PH1 compared to traditional TROP2 ADCs, which exhibited antagonism when paired with adagrasib, emphasizing AKTX-101's uniqueness.
- Innovative Mechanism of Action: PH1 enhances the activity of KRAS inhibitors by targeting pre-mRNA transcripts for degradation, suggesting that RNA splicing modulation could be a new therapeutic strategy for KRAS-driven tumors, which holds significant clinical implications.
- Future Clinical Trial Plans: Akari aims to initiate the first-in-human clinical trial for AKTX-101 by mid-2027, further validating its potential in cancer treatment and demonstrating the company's strategic commitment and research dedication in the oncology field.
See More
Biotech Sector Attracts Investor Attention Amid Innovation
- Investor Enthusiasm: The biotech sector is attracting significant speculative capital due to innovations in next-generation oncology, metabolic diseases, and CNS therapy platforms, indicating strong market interest that could drive stock prices of related companies higher.
- Akari Therapeutics New Data: Akari Therapeutics' ADC candidate AKTX-101 demonstrated synergistic activity in KRAS-mutated pancreatic cancer models, further expanding the potential of its RNA spliceosome-modulating payload platform, which may open new market opportunities for the company.
- NeOnc Technologies Analyst Focus: NeOnc Technologies is gaining attention for its neuro-oncology platform targeting the blood-brain barrier, with multiple analysts issuing “Buy” ratings, which is expected to enhance the company's visibility ahead of anticipated clinical updates.
- MetaVia Research Findings: MetaVia's GPR119 agonist vanoglipel has shown anti-fibrotic potential in new research, indicating its promise in treating metabolic dysfunction-associated steatohepatitis, which may attract further investor interest as clinical data develops.
See More
Akari Therapeutics Shares Surge Over 100% on Breakthrough Data
- Breakthrough Clinical Data: Akari Therapeutics reported that its antibody-drug conjugate AKTX-101 demonstrated synergistic anti-cancer activity when combined with KRAS inhibitor Adagrasib in KRAS-mutated pancreatic cancer models, indicating a potentially powerful combination therapy.
- Efficacy Validation: AKTX-101 achieved Bliss synergy scores exceeding 10 in KRAS-mutant pancreatic cancer cell lines, while traditional TROP2 ADC combinations showed antagonistic effects, underscoring the unique biological mechanism of Akari's PH1 payload.
- Clinical Trial Plans: Akari has initiated IND-enabling studies for AKTX-101 and aims to start its first-in-human clinical trial by mid-2027, showcasing the company's forward-looking strategy in cancer treatment.
- Strong Market Reaction: In pre-market trading, AKTX shares surged from $5.14 to $10.57, reflecting an over 100% increase, indicating high investor confidence and recognition of the new data.
See More
Akari's Cancer Therapy Data Sparks 120% Stock Surge
- Preclinical Data Breakthrough: Akari Therapeutics announced that its lead cancer therapy, AKTX-101, demonstrates strong tumor-killing activity when combined with KRAS inhibitors, particularly in pancreatic cancer models, leading to a 120% surge in shares during after-hours trading, reflecting high market recognition of the therapy's potential.
- Expanded Treatment Opportunities: This data not only supports further development of AKTX-101 but also indicates the broader applicability of RNA splicing-targeted therapies in treating difficult KRAS-driven cancers, potentially transforming current treatment strategies and improving patient survival rates.
- Combination Therapy Advantage: In studies combining AKTX-101 with adagrasib (a KRAS inhibitor), synergistic cell killing was observed in KRAS G12D and G12C mutant cell lines, while other TROP2 ADCs exhibited antagonism, highlighting the unique biological mechanism of AKTX-101.
- Clinical Trial Plans: Akari has initiated IND-enabling studies for AKTX-101, targeting the start of its first-in-human clinical trial by mid-2027, and despite a 55% year-to-date decline in share price, this data release may provide momentum for future clinical advancements.
See More
Multiple Companies Experience Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
- AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
- P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
- Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
See More
Akari Therapeutics Begins Human Trials for AKTX-101
- Preclinical Data Breakthrough: Akari Therapeutics' AKTX-101 demonstrated significantly enhanced efficacy against pancreatic cancer cells with KRAS mutations in lab tests when combined with an approved cancer drug, indicating its potential in treating difficult cancers.
- Funding for Development: The company raised approximately $5.5 million through a private placement, which will be utilized to advance AKTX-101 towards human testing and cover general corporate needs, reflecting strong confidence from strategic investors in the company's future.
- Stock Price Surge: Following the announcement of breakthrough preclinical data, Akari's shares skyrocketed over 133% in after-hours trading, showcasing a strong bullish sentiment in the market, particularly among retail investors whose sentiment shifted from neutral to extremely bullish.
- Optimistic Analyst Ratings: Among the two analysts covering AKTX, one rates it a 'Buy' while the other maintains a 'Hold', with a 12-month average price target of $26.78, suggesting a potential upside of over 420%, despite the stock having fallen 90% over the past year.
See More
Akari Therapeutics' Novel ADC Shows Promise Against KRAS-Driven Cancers
- Novel Drug Combination: Akari Therapeutics' AKTX-101, when combined with the KRAS inhibitor adagrasib, demonstrates synergistic cytotoxic activity in KRAS G12D and G12C mutated pancreatic cancer models, indicating its potential application in difficult-to-treat KRAS-driven cancers.
- Preclinical Data Support: The online abstract presented at the 2026 ASCO Annual Meeting highlights the significant differences of AKTX-101's unique RNA splicing modulator payload PH1 compared to traditional TROP2 ADCs, which exhibited antagonism when paired with adagrasib, emphasizing AKTX-101's uniqueness.
- Innovative Mechanism of Action: PH1 enhances the activity of KRAS inhibitors by targeting pre-mRNA transcripts for degradation, suggesting that RNA splicing modulation could be a new therapeutic strategy for KRAS-driven tumors, which holds significant clinical implications.
- Future Clinical Trial Plans: Akari aims to initiate the first-in-human clinical trial for AKTX-101 by mid-2027, further validating its potential in cancer treatment and demonstrating the company's strategic commitment and research dedication in the oncology field.
See More
